Piramal Pharma Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | no data |
| CEO ownership | n/a |
| Management average tenure | no data |
| Board average tenure | 3.8yrs |
Recent management updates
Recent updates
₹284 - That's What Analysts Think Piramal Pharma Limited (NSE:PPLPHARMA) Is Worth After These Results
Oct 26
Piramal Pharma (NSE:PPLPHARMA) Takes On Some Risk With Its Use Of Debt
Oct 25Here's Why Piramal Pharma (NSE:PPLPHARMA) Has A Meaningful Debt Burden
Jul 14Estimating The Intrinsic Value Of Piramal Pharma Limited (NSE:PPLPHARMA)
Jun 17We Think That There Are Issues Underlying Piramal Pharma's (NSE:PPLPHARMA) Earnings
May 21It's A Story Of Risk Vs Reward With Piramal Pharma Limited (NSE:PPLPHARMA)
Mar 26Estimating The Fair Value Of Piramal Pharma Limited (NSE:PPLPHARMA)
Feb 28Earnings Update: Here's Why Analysts Just Lifted Their Piramal Pharma Limited (NSE:PPLPHARMA) Price Target To ₹161
Feb 02Calculating The Intrinsic Value Of Piramal Pharma Limited (NSE:PPLPHARMA)
Nov 09Calculating The Fair Value Of Piramal Pharma Limited (NSE:PPLPHARMA)
Aug 11CEO
Piramal Pharma has no CEO, or we have no data on them.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairperson | 4.8yrs | ₹42.02m | 0.13% ₹ 464.3m | |
| President | 2.8yrs | ₹24.77m | no data | |
| CEO of Piramal Global Pharma & Director | 4.8yrs | ₹42.40m | 0.033% ₹ 114.6m | |
| Non-Executive Director | 4.2yrs | no data | no data | |
| Independent Non-Executive Director | 3.8yrs | ₹4.35m | 0.0020% ₹ 7.1m | |
| Independent Non-Executive Director | 2.8yrs | ₹4.20m | no data | |
| Independent Non-Executive Director | 2.3yrs | ₹4.25m | no data | |
| Independent Non-Executive Additional Director | 2.8yrs | ₹3.80m | no data | |
| Independent Non Executive Director | 3.8yrs | ₹4.55m | no data |
3.8yrs
Average Tenure
58yo
Average Age
Experienced Board: PPLPHARMA's board of directors are considered experienced (3.8 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/30 21:18 |
| End of Day Share Price | 2024/12/30 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Piramal Pharma Limited is covered by 13 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kunal Randeria | Axis Capital Limited |
| Prakash Agarwal | Axis Capital Limited |
| Rohit Bhat | Batlivala & Karani Securities India Pvt. Ltd. |